Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

• DOI: 10.1007/s12254-012-0061-9
• Publication Date: 2012-12-20T12:03:30Z
• Authors: Walentyna Balwierz; Katarzyna Pawinsk...; Tomasz Klekawka; Malgorzata Czogala; Michal Matysiak; Barbara Fic-Sikorska; Elzbieta Adamkiew...; Lucyna Maciejka-K...; Alicja Chybicka; Kinga Potocka; Jacek Wachowiak; Jolanta Skalska-S...; Jerzy Kowalczyk; Beata Wojcik; Mariusz Wysocki; Sylwia Koltan; Maryna Krawczuk-R...; Katarzyna Muszyns...; Wojciech Mlynarski; Malgorzata Stolarska; Tomasz Urasinski; Elzbieta Kamienska; Tomasz Szczepanski; Renata Tomaszewska; Grazyna Sobol; Agnieszka Mizia-M...; Grazyna Karolczyk; Joanna Podhorecka; Maria Wieczorek; Irena Karpinska-D...; Wanda Badowska; Angelina Moryl-Bu...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Oncology; Hematology; Review; 3. Good health

Since 1983 four consecutive unified regimens: acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group (AML-PPLLSG) 83, AML-PPLLSG 94, 98 and AML-BFM 2004 Interim, for AML have been conducted by the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). In this paper, we review successive studies on basis of leukemia-Berlin-Frankfurt-Munster (AML-BFM) protocol, in which a stepwise improvement treatment outcome was observed. Treatment results last protocol Interim are presented detail.Three hundred three patients with de novo were treated according to at 15 centers from January 1, 2005 June 30, 2011. A confrontation previous periods based upon historical, already published data.In periods, 723 children eligible evaluation (208, 195, 237, respectively). Complete remission rates were: 71, 68, 81 87 %, respectively. The 5-year overall survival rates, event-free relapse-free 33, 32, 45%, respectively 83 regimen; 38, 36, 53 % 94 53, 46, 65 regimen, 63, 52, 64 2004, Incidence early deaths that due complications (mainly infections) first decreased over time 22 4.6 10 5.9 respectively.Despite continuous outcome, number failures still remains too high. Further progress seemed be possible continued cooperation oncology within large international groups.